Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Matrix to submit NDA by year end

MATX released data from two Phase III trials of its IntraDose cisplatin/epiniphrine injectable gel to treat head and

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE